Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Chugh, Sumant S ^a   Macé, Camille ^a   Clement, Lionel C ^a   Avila, Maria Del Nogal ^a   Marshall, Caroline B ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Angiopoietin like 4; Diabetic nephropathy; Focal and segmental glomerulosclerosis; Minimal change disease; N acetyl D mannosamine; Proteinuria; Sialic acids; Therapeutics

Indexed keywords

ANGIOPOIETIN LIKE 4; FATTY ACID; GLUCOCORTICOID; GLYCOPROTEIN; MANNOSAMINE; MUTANT PROTEIN; N ACETYL DEXTRO MANNOSAMINE; RECOMBINANT ANGIOPOIETIN LIKE 4; RECOMBINANT PROTEIN; SIALIC ACID; UNCLASSIFIED DRUG; URINARY TRACT AGENT;

ANGIOPOIETIN LIKE 4 BLOOD LEVEL; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; GLOMERULOPATHY; HUMAN; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; KIDNEY DISEASE; LOW DRUG DOSE; MAINTENANCE THERAPY; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN SECRETION; PROTEINURIA; RELAPSE; REMISSION; REVIEW; SIALYLATION; SKELETAL MUSCLE; TREATMENT RESPONSE; UPREGULATION;

EID: 84895549251     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00023     Document Type: Review

References (28)

1. Bertozzi, C. R., Freeze, H. H., Varki, A., and Esko, J. D. (2009). Essentials of Glycobiology, 2nd Edn, eds A. Varki, R. D. Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, et al. (New York, NY: Cold Spring Harbor Press), 719-732.
2. Chou, H. H., Takematsu, H., Diaz, S., Iber, J., Nickerson, E., Wright, K. L., et al. (1998). A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl. Acad. Sci. U.S.A. 95, 11751-11756. doi: 10.1073/pnas.95.20.11751.
3. Chugh, S. S. (2011a). Methods of Treatment of Nephrotic Syndrome and Related Conditions. International Patent Application PCT/US2011/039255.
4. Chugh, S. S. (2011b). Methods of Treatment. United States Patent Application 20110301103.
5. Chugh, S. S., Clement, L. C., and Macé, C. (2012). New insights into human minimal change disease: Lessons from animal models. Am. J. Kidney Dis. 59, 284-292. doi: 10.1053/j.ajkd.2011.07.024.
6. Clement, L. C., Avila-Casado, C., Macé, C., Soria, E., Bakker, W. W., Kersten, S., et al. (2011). Podocyte-secreted Angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17, 117-122. doi: 10.1038/nm.2261.
7. Clement, L. C., Macé, C., Avila-Casado, C., Joles, J. A., Kersten, S., and Chugh, S. S. (2014). Circulating Angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat. Med. 20, 37-46. doi: 10.1038/nm.3396.
8. Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y. H., Franz, S., Delfgaauw, J., et al. (2008). The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931-938. doi: 10.1038/nm.1857.
9. Georgiadi, A., Lichtenstein, L., Degenhardt, T., Boekschoten, M. V., van Bilsen, M., Desvergne, B., et al. (2010). Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ. Res. 106, 1712-1721. doi: 10.1161/CIRCRESAHA.110.217380.
10. Ghiggeri, G. M., Ginevri, F., Candiano, G., Oleggini, R., Perfumo, F., Queirolo, C., et al. (1987). Characterization of cationic albumin in minimal change nephropathy. Kidney Int. 32, 547-553. doi: 10.1038/ki.1987.243.
11. Kersten, S., Lichtenstein, L., Steenbergen, E., Mudde, K., Hendriks, H. F., Hesselink, M. K., et al. (2009). Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler. Thromb. Vasc. Biol. 29, 969-974. doi: 10.1161/ATVBAHA.108.182147.
12. Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., et al. (2000). Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275, 28488-28493. doi: 10.1074/jbc.M004029200.
13. Koliwad, S. K., Kuo, T., Shipp, L. E., Gray, N. E., Backhed, F., So, A. Y., et al. (2009). Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J. Biol. Chem. 284, 25593-25601. doi: 10.1074/jbc.M109.025452.
14. Koskimies, O., Vilska, J., Rapola, J., and Hallman, N. (1982). Long-term outcome of primary nephrotic syndrome. Arch. Dis. Child. 57, 544-548. doi: 10.1136/adc.57.7.544.
15. Liu, G., Clement, L., Kanwar, Y. S., Avila-Casado, C., and Chugh, S. S. (2006). ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome. J. Biol. Chem. 281, 39681-39692. doi: 10.1074/jbc.M606664200.
16. Malicdan, M. C., Noguchi, S., Hayashi, Y. K., Nonaka, I., and Nishino, I. (2009). Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat. Med. 15, 690-695. doi: 10.1038/nm.1956.
17. Mandard, S., Zandbergen, F., van Straten, E., Wahli, W., Kuipers, F., Müller, M., et al. (2006). The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281, 934-944. doi: 10.1074/jbc.M506519200.
18. Mattijssen, F., and Kersten, S. (2012). Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim. Biophys. Acta 1821, 782-789. doi: 10.1016/j.bbalip.2011.10.010.
19. Papamandjaris, A. A., MacDougall, D. E., and Jones, P. J. (1998). Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. Life Sci. 62, 1203-1215. doi: 10.1016/S0024-3205(97)01143-0.
20. Romeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., et al. (2007). Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39, 513-516. doi: 10.1038/ng1984.
21. Romeo, S., Yin, W., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., et al. (2009). Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119, 70-79. doi: 10.1172/JCI37118.
22. Sillanaukee, P., Pönniö, M., and Jääskeläinen, I. P. (1999). Occurrence of sialic acids in healthy humans and different disorders. Eur. J. Clin. Invest. 29, 413-25. doi: 10.1046/j.1365-2362.1999.00485.x.
23. Staiger, H., Haas, C., Machann, J., Werner, R., Weisser, M., Schick, F., et al. (2009). Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes 58, 579-589. doi: 10.2337/db07-1438.
24. Tarshish, P., Tobin, J. N., Bernstein, J., and Edelmann, C. M. Jr. (1997). Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J. Am. Soc. Nephrol. 8, 769-776.
25. Varki, A., and Schauer, R. (2009). "Sialic acids," in Essentials of Glycobiology, 2nd Edn, eds A. Varki, R. D. Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, et al. (New York, NY: Cold Spring Harbor Press), 199-217.
26. Yin, W., Romeo, S., Chang, S., Grishin, N. V., Hobbs, H. H., and Cohen, J. C. (2009). Genetic variation in ANGPTL4 provides insights into protein processing and function. J. Biol. Chem. 284, 13213-13222. doi: 10.1074/jbc.M900553200.
27. Yoon, J. C., Chickering, T. W., Rosen, E. D., Dussault, B., Qin, Y., Soukas, A., et al. (2000). Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 20, 5343-5349. doi: 10.1128/MCB.20.14.5343-5349.2000.
28. Yoshida, K., Shimizugawa, T., Ono, M., and Furukawa, H. (2002). Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43, 1770-1772. doi: 10.1194/jlr.C200010-JLR200.